Inclusion Criteria:  Male or female patients aged >/=18 years  Patients with a histologically or cytologically:  Confirmed CLL who are refractory to or have progressed from 2 or more regimens including BTKi and venetoclax or Confirmed CLL transformed to DLBCL (Richter Syndrome) who have relapsed after, or been refractory, to at least 1 prior line of therapy for the DLBCL and having MYC overexpression/amplification/translocation Adequate bone marrow, liver, and renal functions Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2  Exclusion Criteria:  Active clinically serious infections of Grade > 2; requiring parenteral therapy Subjects who have new or progressive brain or meningeal or spinal metastases. Anticancer chemotherapy or immunotherapy during the study or within one week prior to the first dose of study drug Major surgery or significant trauma within 4 weeks before the first dose of study drug Allogeneic bone marrow transplant or stem cell rescue within 4 months before first dose of study drug; patients must have completed immunosuppressive therapy before enrollment